Condition 1: Patients with COVID-2019. Condition 2: . COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group:30 patients with COVID-19 in addition to a standard regimen will receive Bromhexine 8 mg tablets every 8 hours for 14 days from the beginning of hospitalization. In
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with COVID-19-induced pneumonia confirmed with PCR Patients or authorized family members volunteered to participate in this study and signed informed consent. Both genders 18 to 80 years old
Exclusion criteria
Exclusion criteria: Patients who are participating in other drug clinical trials Pregnant or lactating women Patient with active thrombotic event Patients with severe respiratory failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization days. Timepoint: At baseline and discharge time. Method of measurement: Counting the days.;Need for mechanical ventilation. Timepoint: From baseline to discharge time. Method of measurement: Observation and documents.;Condition of discharge (death or recovery). Timepoint: End of hospitalization. Method of measurement: Observation and documents.;Period of mechanical ventilation. Timepoint: End of hospitalization. Method of measurement: Documents of hospitalization. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Khalil Ansarin
Tabriz University of Medical Sciences
Outcome results
None listed